CVRx, Inc. Appoints New CFO John Landry

What Happened
CVRx, Inc. announced on September 21, 2026 that its Board appointed John Landry as Chief Financial Officer. Mr. Landry will begin employment on October 12, 2026 to facilitate a transition and will assume CFO responsibilities the day after the company files its Form 10-Q for the quarter ended September 30, 2026. He succeeds Jared Oasheim, who previously gave notice on June 8, 2026 that he intended to resign once his successor begins.

Key Details

• Initial annual base salary: $500,000.
• Target cash incentive: 50% of base salary (pro-rated for fiscal 2026).
• Initial equity package: awards equal to 0.80% of total common shares outstanding at his start date, composed of 75% stock options and 25% restricted stock units, with a 1.5:1 multiple of options to RSUs; granted under Nasdaq inducement exemption.
• Other terms: payment of a forfeited pro‑rated bonus from his current employer (subject to recoupment if he resigns or is fired for cause within one year), reimbursement of travel from his residence, and the Company’s standard executive severance agreement.
• Background: Age 54; currently CFO of Nyxoah SA (since Nov 2024); prior CFO roles at Vapotherm (2012–2024) and other finance leadership roles at Medtronic/Salient Surgical, Bottomline Technologies, Hussey Seating and Coopers & Lybrand.

Why It Matters
A CFO change is a material leadership transition that can affect financial strategy, reporting and investor relations. The filing signals a planned, managed handoff (with a defined start date and transitional timing tied to the Q3 Form 10‑Q) and discloses the compensation and equity structure for the incoming CFO. Investors may watch for any shifts in financial guidance, reporting cadence, or capital allocation policies under the new finance leadership.